Clinical Trials on Suicide, Completed in Russian Federation

Total 8 results

Meshalkin Research Institute of Pathology of Circulation

Unknown

Radiofrequency Ablation of Symptomatic Frequent Ventricular Premature Complexes in Pediatric Population (RAS)

Ventricular Arrhythmia

Russian Federation
N.N. Petrov National Medical Research Center of...

Recruiting

Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB) (VAB)

Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB

Russian Federation
Alexander Khitaryan

Recruiting

3D vs 2D-laparoscopy for Rectocele and Rectal Prolapse Correction: a Prospective, Randomized, Single Center Study (LARC)

Rectal Prolapse | Rectocele; Female | Rectocele and Incomplete Uterine Prolapse | Rectocele and Complete Uterovaginal Prolapse

Russian Federation
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Major Depressive Disorder With Suicidal Ideation With Intent

Taiwan, Spain, Germany, Netherlands, Turkey, Mexico, United States, Malaysia, Poland, Canada, Japan, Russian Federation, Argentina, Brazil
Amgen

Completed

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

United States, Poland, France, Russian Federation, Spain, Australia, Greece, Switzerland, Brazil
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more

Clinical Trials on Suicide, Completed in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations